The migraine headache treatment developed by Pozen (NASDAQ:POZN) now has a partner for commercialization in Europe. Pozen licensed the compound MT 400 to German central nervous system therapies company Desitin in a deal that will pay the Chapel Hill, North Carolina drug developer $3 million up front, plus milestones and royalties from drug sales in […]
Osteoarthritis drug Vimovo‘s sales disappointed early and its U.S. prescriptions have declined as of late, but for all of those commercialization pains, the drug has become an unexpected regulatory beacon for Pozen‘s (NASDAQ:POZN) latest drug candidate. PA32540 is Pozen’s safer aspirin, a compound drug that the Chapel Hill, North Carolina company developed for secondary prevention […]
Pozen (NASDAQ:POZN), now prepping to file a new drug application for its safer form of aspirin, has run into a slight regulatory headache. The company had looked on track way for a third-quarter drug filing on its combination aspirin product that targets the large market for cardiovascular disease prevention. Pozen even got its phase 3 […]
The delayed-release aspirin compound that Pozen (NASDAQ:POZN) has developed to protect against cardiovascular disease showed in clinical trials that it causes fewer ulcers compared to aspirin alone. With those positive phase 3 clinical trial results in hand, Pozen now expects to file a new drug application on PA32540 in the third quarter. John Plachetka, CEO […]
Arthritis represents a large medical need but it is served by several products that carry gastrointestinal risks. Arthritis treatment Vimovo, developed as an alternative that’s easier on the stomach, was intended to address that need. Backed by the marketing muscle of pharma giant AstraZeneca (NYSE:AZN), Pozen (NASDAQ:POZN), which developed the drug, had every expectation it […]
For a glimpse into social media’s coming role in pharmaceutical sales and marketing, and the digital health of tomorrow, consider its use in Gatorade’s marketing today. The Gatorade Company maintains a “mission control center” in the heart of the company’s marketing floor, said Bonin Bough, director of digital and social media for parent company PepsiCo […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
As drug partnering auditions go, Pozen (NASDAQ:POZN) has played this role before: The small drug developer flirts with a large pharmaceutical company who has the resources and the reach to take its promising drug candidate global. Many companies audition without so much as a callback from Big Pharma. Chapel Hill, North Carolina-based Pozen has already […]
Pozen (NASDAQ:POZN) CEO John Platchetka likens the drug partnering process to a relay race. One runner at full speed finishes and hands the baton to another runner at full speed to finish the race. That’s the ideal. But in many cases, Big Pharma isn’t yet running when it receives the baton. Pozen developed migraine treatment […]
The new cardiovascular drug being developed by Pozen (NASDAQ:POZN) does not yet even have a name, but it now has a manufacturer to produce it once it secures U.S. Food and Drug Administration approval. The Chapel Hill, North Carolina pharmaceutical company has reached a supply agreement with contract drug manufacturer Patheon (TSX:PTI), according to securities […]
To understand why Pozen (NASDAQ:POZN) sold future U.S. royalty rights for migraine drug Treximet, its lead revenue-generating product, it helps to understand what the company is doing with its drug pipeline right now. Chapel Hill, North Carolina-based Pozen has been directing resources to its PA drug platform, chiefly drug candidate PA32540, which is in phase […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Pozen (NASDAQ:POZN) has sold the U.S. royalty rights for migraine drug Treximet to Canada’s national pension fund, CPPIB Credit Investments in a $75 million deal. The terms of the deal give the Chapel Hill, North Carolina pharmaceutical company a 20 percent interest in any royalties received by the pension fund starting April 1, 2018, according to […]
If you only looked at Pozen‘s (NASDAQ:POZN) top and bottom lines from its third-quarter earnings, you might have missed a key detail affecting the pharmaceutical company’s financial performance. Although Chapel Hill, North Carolina-based Pozen’s revenue grew and its loss narrowed in the third quarter, the company insists results should be better and management pins those […]
Digital drug marketing has been pharmaceutical company Pozen‘s (NASDAQ:POZN) mantra for much of this year. The Chapel Hill, North Carolina-based company has made clear that when it goes to market with its new cardiovascular drug, a digital strategy will dictate its reach to patients and physicians in ways that traditional pharmaceutical sales representatives have not […]
The digital communication consumers favor today to discuss retail products and food might have more to say about the future of pharmaceutical marketing than the still-ubiquitous television commercials promoting the latest lifestyle drugs. Pozen (NASDAQ:POZN), a Chapel Hill, North Carolina drug-development company, took the unusual step in July of appointing a digital advisory board whose […]
Pozen‘s (NASDAQ:POZN) patent fight to protect its migraine headache drug Treximet is not yet over. The Chapel Hill, North Carolina-based pharmaceutical company won a patent litigation court victory last month when a federal judge in Texas ruled that Pozen’s drug patents for Treximet were valid and enforceable. But Pozen disclosed in securities filings that generic […]
